Mark Bamforth
Angel Investor · at Thairm Bio
Boston, United States
Mark Bamforth is a Series A investor at Thairm Bio in Boston focused on Health Care and Medical. Mark Robert Bamforth is based out of Boston, Massachusetts and is the Chief Executive Officer of disAMR and Executive Advisor of Ampersand Capital Partners. Mark previously worked at Kincell Bio as a Chief Executive Officer. Mark Robert Bamforth attended the Henley Business School.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Mark Bamforth invests in
Stages Mark Bamforth invests in
Countries Mark Bamforth invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $2M–$7M
- Series A
- $9.2M–$21M
Investment Focus
Industry
- Health Care 6 (40%)
- Medical 5 (33%)
- Biotechnology 4 (27%)
- Machine Learning 3 (20%)
- Therapeutics 2 (13%)
Stage
- Series A 4 (27%)
- Funding Round 3 (20%)
- Seed 2 (13%)
- Series B 1 (7%)
- Venture - Series Unknown 1 (7%)
Country
- United Kingdom 6 (40%)
- United States 3 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections. The company's offerings include developing and advancing novel microbiome-modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in thehuman gut, enabling physicians to prevent and treat debilitating infections and diseases. | $25.7M / Venture - Series Unknown / Apr 29, 2026 | ||
| 3Daughters is a women’s healthcare company developing a new evolutionary intrauterine device (IUD) for contraception. | $2.7M / Seed / Jul 10, 2024 | ||
| Phlo is a digital pharmacy delivering NHS & Private prescriptions when and where you need them. Phlo works with both repeat and acute (one-off) prescriptions.Phlo uses technology and analytics to place patients at the heart of our business, providing patients with real-time, on-demand delivery of their acute and repeat prescriptions.Phlowas established in January, 2019 in London, England by Nadeem Sarwar. | $11.2M / Venture - Series Unknown / Apr 17, 2024 | ||
| 3Daughters is a women’s healthcare company developing a new evolutionary intrauterine device (IUD) for contraception. | $2M / Seed / Jan 22, 2024 | ||
| Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilitiesin glycobiology. | $10M / Venture - Series Unknown / Jun 01, 2023 | ||
| Thymmune Therapeutics is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. | $7M / Seed / Mar 01, 2023 | ||
| Phlo is a digital pharmacy delivering NHS & Private prescriptions when and where you need them. Phlo works with both repeat and acute (one-off) prescriptions.Phlo uses technology and analytics to place patients at the heart of our business, providing patients with real-time, on-demand delivery of their acute and repeat prescriptions.Phlowas established in January, 2019 in London, England by Nadeem Sarwar. | $12.2M / Series A / Feb 02, 2023 | ||
| Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business hasgenerated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy.Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker. | $9.3M / Series A / Feb 01, 2023 | ||
| PneumoWave is developing real-time monitoring solutions to allow patients with respiratory conditions and their doctors to track their respiratory rates and performance out of hospital, at home and at work. Combining proprietary sensor technology and an innovative AI driven digital therapeutic software platform, PneumoWave's technologyenables doctors to rationalise medication use, identify early signs of deterioration, reduce or shorten hospital admissions and reduce face to face appointments. | $9.2M / Series A / Jan 12, 2023 | ||
| Data tech innovator Talking Medicines, based in Glasgow and London, uses advanced AI and ML to provide pharmaceutical companies with real-time data intelligence. The company uses a collection of AI, ML and NLP tech tools to capture and structure the voice of the patient from real world conversations and behaviours at home. Through mapping thepatient voice from social media and connected devices to regulated medicine information, the company is able to build data points to deliver trends and patterns of patient sentiment across medicines. This intelligence embraces regulatory compliance enabling marketing in pharmaceutical companies to measure patient confidence by medicine and in turn action the levers for share growth. | $2M / Venture - Series Unknown / Feb 01, 2022 | ||
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Mark Bamforth invest in?
Mark Bamforth invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Funding Round stage. Most of the 15 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Mark Bamforth's check size?
Mark Bamforth typically joins rounds of $2M–$7M at Seed and $9.2M–$21M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Mark Bamforth participates in.
How do I contact Mark Bamforth?
Public channels for Mark Bamforth include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Mark Bamforth last invest?
The most recent investment recorded for Mark Bamforth closed in Apr 2026. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
